Scientists hunt for genetic signs to personalize bile duct cancer therapy
NCT ID NCT06648057
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study enrolls 100 adults with advanced biliary tract cancer who are already scheduled to receive a combination of two drugs (lenvatinib and pembrolizumab). Researchers will collect blood and tumor samples to look for genetic markers that might predict who responds best to treatment. The goal is to understand why some patients benefit more than others, not to test a new treatment directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Bundang CHA Medical Center
RECRUITINGSeongnam-si, Gyeonggi-do, 13496, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••